Off-label use of orphan medicinal products: a Belgian qualitative study

被引:15
|
作者
Dooms, Marc [1 ]
Cassiman, David [2 ]
Simoens, Steven [3 ]
机构
[1] Univ Hosp Leuven, Ctr Clin Pharmacol, Herestr 49, B-3000 Leuven, Belgium
[2] Univ Hosp Leuven, Div Gastroenterol Hepatol, Herestr 49, B-3000 Leuven, Belgium
[3] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Herestr 49,POB 521, B-3000 Leuven, Belgium
关键词
Off-label use; Unlicensed use; Orphan medicinal products; Rare diseases; Safety; Efficacy; PERSPECTIVE;
D O I
10.1186/s13023-016-0507-y
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Off-label use of (orphan) medicinal products for (rare) diseases is quite common but not underpinned by clinical studies to confirm efficacy and safety. No risk-analyses by regulatory agencies are carried out. The objective of this study was to map off-label use of orphan medicinal products in Belgium in terms of attitude towards off-label prescribing, factors influencing off-label prescribing, disclosure of information towards the patient, reporting of off-label use, risks and consequences. Most of the EMA authorized orphan drugs are fully reimbursed in Belgium under well-defined circumstances. Moreover, a "Special Solidarity Fund" takes care of some specific cases eventually prescribed off-label. Methods: Semi-structured interviews with seven physicians with expertise in the treatment with and six experts in the reimbursement of orphan medicinal products in Belgium. This task was performed by five last-year pharmacy students after having studied profoundly the medical literature around off-label prescribing. They had no previous contact with the participants. Results: Most participants do agree with the off-label use if the medicinal product is quite safe and well-tolerated, if the on-label indication is rather general and when all other options have failed in some specific, evidence-based indications, especially in children. Before starting off-label use, the patient/family needs to be fully and clearly informed. The treatment is not reimbursed but sometimes sponsored by the company or by charity funds. Reporting of the outcome is necessary to avoid losing valuable information. The prescriber is responsible and can be held accountable. Conclusions: While there is support from physicians and reimbursement experts, there is also concern in case of off-label use, mainly for reasons of patient safety especially when medicinal products are prescribed off-label in the absence of medical or scientific justification and driven by cost-containment motives.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 50 条
  • [22] The use of "off-label"' drugs
    Broadman, LM
    Semenov, I
    ANESTHESIA AND ANALGESIA, 2006, 103 (01): : 250 - 251
  • [23] Off-label use of medicines
    C. A. Yeung
    British Dental Journal, 2017, 222 : 495 - 496
  • [24] Off-Label Use Reimbursement
    Cohen, Joshua
    Wilson, Andrew
    Faden, Laura
    FOOD AND DRUG LAW JOURNAL, 2009, 64 (02) : 391 - 403
  • [26] A Hemorrhage of Off-Label Use
    Karkouti, Keyvan
    Levy, Jerrold H.
    ANNALS OF INTERNAL MEDICINE, 2011, 155 (05) : 339 - 339
  • [27] QUETIAPINE OFF-LABEL USE
    Levin, R.
    Cosmatos, I
    Dieck, G.
    Reifsnyder, J.
    VALUE IN HEALTH, 2016, 19 (07) : A522 - A522
  • [28] Methylphenidate Off-label Use
    Trenque, T.
    DRUG SAFETY, 2012, 35 (10) : 891 - 891
  • [29] Off-label use of vaccines
    Neels, Pieter
    Southern, James
    Abramson, Jon
    Duclos, Philippe
    Hombach, Joachim
    Marti, Melanie
    Fitzgerald-Husek, Alanna
    Fournier-Caruana, Jacqueline
    Hanquet, Germaine
    VACCINE, 2017, 35 (18) : 2329 - 2337
  • [30] Off-label use in neurology
    Diener, HC
    AKTUELLE NEUROLOGIE, 2002, 29 (08) : 379 - 381